

Reversal Agent	Idarucizumab	Andexanet alfa	Ciraparantag PER977
Target	Dabigatran	Factor Xa Inhibitors	Universal except warfarin and argatroban
Mechanism	Humanized Fab specifically binds to dabigatran	Recombinant human Fxa decoy: competitive affinity for direct Fxa inhibitors	Synthetic small molecule: charge-charge interactions
Onset of Action	10-30 minutes	2-5 minutes	10 minutes
Half-Life	45 minutes	60 minutes	45 minutes
Status	Approved in 2015	Approved in 2018	Under FDA Review

**Table 3**

**Reversal agents for direct oral anticoagulants (DOACs)**

